Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 1.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,367,759 shares of the company's stock after purchasing an additional 26,145 shares during the quarter. Geode Capital Management LLC owned about 2.33% of Twist Bioscience worth $61,807,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Principal Financial Group Inc. lifted its holdings in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company's stock worth $6,057,000 after purchasing an additional 83,287 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock valued at $1,324,000 after acquiring an additional 20,035 shares during the period. FMR LLC lifted its stake in Twist Bioscience by 6.0% during the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock valued at $9,875,000 after acquiring an additional 12,327 shares during the period. Barclays PLC boosted its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after acquiring an additional 104,420 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock worth $1,718,000 after acquiring an additional 21,357 shares during the period.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $4.32 during midday trading on Friday, reaching $47.94. 2,277,375 shares of the company's stock traded hands, compared to its average volume of 946,053. The company has a fifty day simple moving average of $45.35 and a two-hundred day simple moving average of $46.75. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The company has a market cap of $2.85 billion, a P/E ratio of -13.32 and a beta of 1.82.

Insiders Place Their Bets

In related news, SVP Paula Green sold 3,310 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the transaction, the senior vice president now directly owns 84,585 shares of the company's stock, valued at approximately $3,654,917.85. This represents a 3.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 3,104 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $134,123.84. Following the sale, the insider now directly owns 75,289 shares in the company, valued at approximately $3,253,237.69. This trade represents a 3.96 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 99,659 shares of company stock worth $4,484,602. Company insiders own 3.92% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Leerink Partners upped their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Scotiabank upped their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. Robert W. Baird boosted their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday, November 19th. Finally, Evercore ISI raised their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.